-

RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial

This Study Will Help Assess the Time Necessary for Tetranite® to Regenerate Bone in the Oral Environment

original Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.

This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted.

“We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” said Dr. Sinjari. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.”

Currently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval.

Dr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto. “I believe this technology will be transformative in the way we place dental implants.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.

Contacts

Michael Tiedemann
mtiedemann@revbio.com

Industry:

RevBio, Inc.

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)
Hashtags
#Biomaterials
#Bone
#BoneAdhesive
#BoneGlue
#ChietiUniversity
#ClinicalTrial
#Dental
#MedicalDevice
#Research
#RevBio
#TETRANITE

Contacts

Michael Tiedemann
mtiedemann@revbio.com

Social Media Profiles
RevBio on Instagram
RevBio on LinkedIn
RevBio on Vimeo
RevBio on Twitter
More News From RevBio, Inc.

REVBIO Publishes in NPJ Microgravity the Results of its TETRANITE® Bone Regeneration Study Conducted Onboard the International Space Station

LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., has published peer reviewed results of a study in NPJ Microgravity, an open-access journal from the Nature portfolio, showing that its regenerative bone adhesive, TETRANITE®, promotes localized new bone growth in a microgravity environment where the ability to regenerate new bone tissue is significantly compromised.1 A key objective of the study was to compare the ability of TETRANITE, a patented regenerative biomaterial, to generate new bone compar...

FDA Greenlights RevBio’s Pivotal Clinical Trial for its Cranial Flap Bone Glue

LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use TETRANITE® to reintegrate cranial bone flaps, which are portions of the skull that are temporarily removed by neurosurgeons to perform brain surgery. This clinical trial is designed to demonstrate that TETRANITE can immediately fixate cranial flaps and enable bone fusion in cranioto...

RevBio® Receives Approval from FDA to Start a Dental Clinical Trial for its Regenerative Bone Glue

LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a pilot clinical trial to examine the safety and efficacy of TETRANITE®, the company’s regenerative bone adhesive, to perform dental ridge augmentation procedures without the need for ancillary containment devices like membranes or meshes or fixation aids like tacks and screws. “The ability for the product to adhere to the surrounding bony walls of a site tha...
Back to Newsroom